CellCentric Ltd.
Venetoclax(CellCentric Ltd.)은 Precursor Cell Lymphoblastic Leukemia-Ly 표적 치료제로, Haematological Malignancy; Acute Myeloid Leukemia 영역에서 개발·상용화 중입니다. 작용기전: Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Phase 3 후기 임상 단계입니다. This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in trea…. PK: t½ 26 h. 차별점: first-in-class, FDA-approved small molecule activator of the mitochondrial ATP-dependent caseinolytic peptidase P (ClpP).
Precursor Cell Lymphoblastic Leukemia-Ly
Haematological Malignancy; Acute Myeloid Leukemia
Recruiting
CAR-T: An Australian multi-centre cohort study
calicheamicin (CAL)
first-in-class, FDA-approved small molecule activator of the mitochondrial ATP-dependent caseinolytic peptidase P (ClpP)
Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein
immune-mediated destruction
DNA damage was detected by Comet assay, 53BP1, phospho-S*Q, and γH2A
biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets
downregulation of phosphorylated Rb, c-Myc (Myc), and lamin B1, upregulation of senescent-associated secretory phenotype (SASP), and e
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
CellCentric Ltd.
Venetoclax(CellCentric Ltd.)은 Precursor Cell Lymphoblastic Leukemia-Ly 표적 치료제로, Haematological Malignancy; Acute Myeloid Leukemia 영역에서 개발·상용화 중입니다. 작용기전: Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Phase 3 후기 임상 단계입니다. This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in trea…. PK: t½ 26 h. 차별점: first-in-class, FDA-approved small molecule activator of the mitochondrial ATP-dependent caseinolytic peptidase P (ClpP).
Precursor Cell Lymphoblastic Leukemia-Ly
Haematological Malignancy; Acute Myeloid Leukemia
Recruiting
CAR-T: An Australian multi-centre cohort study
calicheamicin (CAL)
first-in-class, FDA-approved small molecule activator of the mitochondrial ATP-dependent caseinolytic peptidase P (ClpP)
Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein
immune-mediated destruction
DNA damage was detected by Comet assay, 53BP1, phospho-S*Q, and γH2A
biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets
downregulation of phosphorylated Rb, c-Myc (Myc), and lamin B1, upregulation of senescent-associated secretory phenotype (SASP), and e
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.